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Abstract
Background: Blocking the mechanistic target of rapamycin complex-1 (mTORC1) with chemical inhibitors such as
rapamycin has shown limited clinical efficacy in cancer. The tumor microenvironment is characterized by an acidic
pH which interferes with cancer therapies. The consequences of acidity on the anti-cancer efficacy of mTORC1 inhibitors
have not been characterized and are thus the focus of our study.
Methods: Cancer cell lines were treated with rapamycin in acidic or physiological conditions and cell proliferation was
investigated. The effect of acidity on mTORC1 activity was determined by Western blot. The anticancer efficacy of
rapamycin in combination with sodium bicarbonate to increase the intratumoral pH was tested in two different mouse
models and compared to rapamycin treatment alone. Histological analysis was performed on tumor samples to evaluate
proliferation, apoptosis and necrosis.
Results: Exposing cancer cells to acidic pH in vitro significantly reduced the anti-proliferative effect of rapamycin. At the
molecular level, acidity significantly decreased mTORC1 activity, suggesting that cancer cell proliferation is independent of
mTORC1 in acidic conditions. In contrast, the activation of mitogen-activated protein kinase (MAPK) or AKT were not
affected by acidity, and blocking MAPK or AKT with a chemical inhibitor maintained an anti-proliferative effect at low pH.
In tumor mouse models, the use of sodium bicarbonate increased mTORC1 activity in cancer cells and potentiated the
anti-cancer efficacy of rapamycin. Combining sodium bicarbonate with rapamycin resulted in increased tumor necrosis,
increased cancer cell apoptosis and decreased cancer cell proliferation as compared to single treatment.
Conclusions: Taken together, these results emphasize the inefficacy of mTORC1 inhibitors in acidic conditions. They further
highlight the potential of combining sodium bicarbonate with mTORC1 inhibitors to improve their anti-tumoral efficacy.
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Background
Tumor cells preferentially perform glycolysis despite the
presence of oxygen [1]. Consequently, an increased
quantity of H+ is generated, creating a hostile environ-
ment characterized by acidic extracellular pH. In
addition, tumors frequently present hypoxic regions due
to insufficient blood supply, also promoting anaerobic
metabolism and the formation of lactic acid [2]. Emerging
evidence highlights that acidic tumor microenvironment
not only promotes tumor progression, invasion and
metastasis but also induces drug resistance [3–5]. Accord-
ingly, therapeutic strategies that interfere with acid-base
regulation have demonstrated anti-tumor activity in a var-
iety of pre-clinical studies [6]. One of these strategies con-
sists of oral administration of sodium bicarbonate in order
to increase the intra-tumoral pH, resulting in an inhibition
of tumor growth and metastasis formation in murine
models [3, 7, 8]. Furthermore, sodium bicarbonate poten-
tiates the efficacy of weak base chemotherapies such as
doxorubicin presumably by enhancing drug uptake [5].
The complex 1 of the mechanistic target of rapamycin
(mTORC1) represents a promising target in cancer ther-
apies as it is frequently activated in cancer and as it con-
trols cell growth [9, 10]. mTORC1 is composed of five
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different proteins: mTOR, Raptor, mLST8, PRAS40 and
Deptor. The precise functions of mTORC1 components
are still not fully characterized. Nevertheless, it was
shown that Raptor positively regulates mTORC1 activity
presumably by regulating the assembly of the complex
and by recruiting substrates for mTOR [11, 12].
mTORC1 activity is regulated by a variety of stimuli.
Whereas growth promoting factors induce mTORC1
activity, unfavorable growth conditions such as hypoxia
or acidity generally lead to its inhibition [13, 14]. Once
activated, mTORC1 regulates multiple cellular processes
implicated in cell growth including protein, lipid and nu-
cleotide synthesis [13]. Several studies have outlined the
potential of inhibiting mTORC1 by rapamycin or its an-
alogs termed rapalogs to reduce tumor progression in
experimental models and to increase progression free
survival in tumor patients [15, 16]. Unfortunately, simi-
lar to other targeted therapies, cancers relapse after an
initial response to mTORC1 inhibition through the de-
velopment of resistance mechanisms by cancer cells.
Most identified resistance mechanisms involve the abol-
ishment of negative feedback loops induced by mTORC1
inhibition, resulting in the activation of other prolifera-
tive signals [17–19]. In particular, loss of mTORC1/
S6K1 mediated IRS-1, Grb10 and Sin-1 phosphorylation
leads to aberrant overactivation of mTORC2/AKT
signaling pathway which promotes tumorigenesis
[19–21]. Therefore, therapeutic strategies overcoming
these resistances against mTORC1 inhibitors need to
be developed.
Although several resistance mechanisms to rapalogs,
most of them implicated in intracellular processes, have
been identified, little is known about the influence of
acidic tumor microenvironment on the anti-cancer effi-
cacy of these inhibitors. In the current work, we demon-
strate that acidity reduces the antiproliferative effects of
rapamycin in vitro and that sodium bicarbonate potenti-
ates the anti-cancer activity of rapamycin in vivo. Thus,
our findings identify the acidic tumor microenvironment
as a novel parameter of resistance to mTORC1 inhibi-
tors and provide a rationale to combine strategies that
increase the intra-tumoral pH with mTORC1 inhibitors
in cancer therapy.
Methods
Cell culture, reagents, antibodies
Human colorectal adenocarcinoma cell line HT29,
human renal cell carcinoma cell lines 786–0 and Caki-1
as well as human hepatocellular carcinoma cell line
PLC-PRF/5 were purchased from ATCC. Murine colon
adenocarcinoma cell line MC-38 were kindly provided
by Dr. Jeffrey Schlom (National Cancer Institute, NIH,
Bethesda, MD, USA) [22]. Cell lines were cultured in
Dulbecco’s Modified Eagle’s Medium-high glucose
(DMEM) (Sigma-Aldrich) supplemented with 10% FBS
and 1% streptomycin/penicillin. Rapamycin (#R-5000)
and U0126 (#U-6770) were from LC Laboratories.
MK-2206 was from Selleck Chemicals (#S1078). Sodium
bicarbonate and HEPES (4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid) were from Sigma-Aldrich. For
cell culture, rapamycin was dissolved in dimethyl sulfox-
ide (DMSO). For in vivo experiments, rapamycin was
dissolved in DMSO and diluted 1:5 in PBS-Tween-PEG
(89.6% phosphate-buffered saline (PBS), 5.2% Tween 20,
5.2% poly (ethylene glycol)). For immunohistochemical
staining, the following primary antibodies and concen-
trations were used: anti-phospho S6 ribosomal protein
antibody (1:100) (M3500; Spring Bioscience Corpor-
ation), anti-PCNA antibody (1:50) (ab2426; Abcam) and
anti-cleaved Caspase-3 antibody (1:200) (#9661; Cell Sig-
naling Technology). For Western blot analysis, the fol-
lowing primary antibodies and concentrations were
used: Anti-phospho S6 ribosomal protein antibody
(1:2000) (M3500; Spring Bioscience Corporation), anti-
S6 ribosomal protein antibody (1:1000) (#2217; Cell Sig-
naling Technology), anti-raptor antibody (1:1000)
(#2280; Cell Signaling Technology), anti-phospho-Akt
antibody (1:500) (#4060; Cell Signaling Technology),
anti-Akt antibody (1:1000) (#2920; Cell Signaling
Technology), anti-p44/42 MAPK antibody (1:1000)
(#9102; Cell Signaling Technology), anti-phospho-p44/
42 MAPK antibody (1:1000) (#9101; Cell Signaling
Technology), anti-phospho-4E-BP1 (Thr37/46) antibody
(1:1000) (#2855; Cell Signaling Technology), anti-
phospho-4E-BP1 (Ser65) antibody (1:1000) (#9451; Cell
Signaling Technology), anti-4E-BP1 antibody (1:1000)
(#9644; Cell Signaling Technology) and anti-actin anti-
body (1:5000) (#A2228; Sigma Aldrich).
Proliferation assay
Cancer cells were plated in 96 well plates at 10 000 cells
per well, cultured in DMEM adjusted to different pH
using HEPES and treated with DMSO, rapamycin (100
nM), MK-2206 (1 μM) or UO126 (10 μM) for 48 h.
Cellular proliferation was monitored after 48 h with
CellTiter 96 AQueous One Solution Cell Proliferation
Assay (MTS) (Promega) by following the manufacturer’s
instructions. Absorbance at 492nm was measured 30
min after compound addition. Experiment was per-
formed in quadruplicates and repeated three times.
Stable transfection
Lentiviruses were generated by transfecting HEK-293T
cells with the following plasmids: psPAX2 (plasmid
#12260, Addgene) and pMD2.G (plasmid #12259,
Addgene) together with raptor_1 shRNA (plasmid
#1857, Addgene) or a control shRNA (plasmid #1864,
Addgene) using FuGENE and following the manufacturer’s
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instructions [23]. Supernatants were collected and used to
infect HT29 cells. Stable transfectants were selected for
resistance to puromycin (10 μg/ml). Efficiency of raptor
downregulation was tested by Western blot.
Western blot analysis
Cell lines were plated in 6 well plates at 100 000 cells
per well and cultured in DMEM adjusted to different pH
using HEPES. Cells were cultured at different pH for dif-
ferent times and treated with rapamycin 100 nM or
DMSO as indicated. Cells were lysed in RIPA buffer.
Protein concentrations were measured using BCA Assay
(Pierce). Equal amounts of protein (20 μg) were sepa-
rated on 4–12% polyacrylamide gel and subsequently
transferred to a polyvinylidene difluoride membrane
(Millipore). Membranes were blocked with Odyssey
blocking buffer (LI-COR Biosciences) and immuno-
blotted with primary antibodies followed by infrared sec-
ondary antibodies. Bands from immunoreactive proteins
were visualized by an Odyssey infrared imaging system
(LI-COR Biosciences).
Immunohistochemistry
Xeno- and allografts were fixed in 4% formaline over-
night, dehydrated with ethanol and paraffin-embedded.
Sections of 3 μm were obtained using MICROM HM
355S microtome (Thermo Scientific), and tissue sections
were mounted on Superfrost Plus slides (Thermo
Scientific). Slides were then deparaffinized and rehy-
drated with xylol and alcohol. After antigen retrieval
(citrate pH 6.0 or TRIS/EDTA pH 9.0), sections were
immunostained using above-mentioned primary anti-
bodies for 60 min and subsequently incubated with
Dako EnVision HRP secondary antibody (Dako) for 30
min. Counterstaining of nuclei and controls with sec-
ondary antibodies only were performed. In parallel,
staining with haematoxylin and eosin were performed.
One section from each xenograft and allograft tumor
and three tumors for each condition were analyzed for
each staining. Carl Zeiss Axioscope, AxioCam MRc and
AxioVision 40V 4.6.3.0 software (Carl Zeiss Vision) were
used for imaging acquisition and processing. Histology
analysis was performed by two researchers blinded to
groupings. Percentage of tumor necrosis (light pink
stained surface in H & E) and phospho S6 expression
(phospho S6 positive surface) were measured quantita-
tively using ImageJ 1.46r Threshold Colour Plugin by
analyzing 10 representative images of 3368 × 2668 μm
for each condition in three different tumors. PCNA posi-
tive and PCNA negative cancer cells and cleaved caspase
3 positive and cleaved caspase 3 negative cancer cells
respectively were counted in 10 representative vital
tumor zones of a 100 × 100 μm surface for three differ-
ent HT29 and MC-38 tumors. Percentage of PCNA
positive and cleaved caspase 3 positive cells were calcu-
lated by dividing the number of PCNA or cleaved
caspase 3 positive cancer cells by the number of PCNA
or cleaved caspase 3 positive and negative cancer cells
respectively.
Mouse models
Animal experiments were in accordance with the Swiss
federal animal regulations and approved by the local vet-
erinary office. Female nude and C57BL/6 eight-week old
mice were purchased from Janvier Labs. Mice were ran-
domized into different groups (n = 5/group; groups “ve-
hicle” - “bicarbonate” - “rapamycin” - “bicarbonate and
rapamycin”). HT29 (3 × 106) and MC-38 (1 × 106) cells
were injected subcutaneously into the right flank.
Sodium bicarbonate was added to the drinking water at
a concentration of 200 mmol/L, starting 1 day before
cancer cell injection. Once the tumor xeno-/allografts
reached a mean volume of 25 mm3, mice were treated
once daily with rapamycin (3 mg/kg body weight, intra-
peritoneally, in 20 μl DMSO and 80 μl PBS-Tween-PEG)
or vehicle (20 μl DMSO and 80 μl PBS-Tween-PEG).
Tumor volumes were measured daily using a caliper and
calculated with the formula V = A * B * C * π/6 where A
is the length, B the width and C the height of the tumor.
Animals were sacrificed once the biggest tumor of
vehicle treated mice reached the size of 1 000 mm3
(defined as interruption criterion according to veterinary
recommendations). Tumors were excised and samples
processed for immunohistochemical analysis.
Statistics
Statistical analysis including Student’s t-test, One-way
ANOVA and Two-way ANOVA were carried out as ap-
propriate using GraphPad Prism version 6.05.
Results
mTORC1 inhibition does not reduce cancer cell proliferation
in acidic conditions
We first investigated whether extracellular pH influences
the antiproliferative efficacy of rapamycin. To test this,
human HT29 colon cancer cells were cultured under
various pH conditions and treated with rapamycin. Cell
proliferation was monitored after 48 h of treatment.
Rapamycin significantly reduced cancer cell proliferation
by 37.1% (p < 0.0001) under physiological pH. This effect
was however lost when cancer cells where cultured at
pH 6.8 or 6.4 (Fig. 1a). For comparison, we treated
HT29 cells with MK-2206, a chemical inhibitor of AKT,
and U0126, a chemical inhibitor of mitogen-activated
protein kinase kinase 1/2 (MEK1/2). In contrast to rapa-
mycin treatment, MK-2206 and U0126 still significantly
reduced cell proliferation in acidic conditions (Fig. 1a).
The loss of efficacy of rapamycin in acidic conditions
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was not restricted to HT29 cells as we found similar
results with a larger panel of cancer cells including human
renal carcinoma cell lines (786–0, Caki-1), human hepato-
cellular cancer cell lines (Huh7, PLC-PRF/5) and murine
colon adenocarcinoma cell line (MC-38) (Fig. 1b).
To exclude a loss of rapamycin efficacy by inactivation
in acidic conditions we performed the following
experiment. Rapamycin was incubated for 24 h at a con-
centration of 1 μM in medium buffered at pH 6.4 or 7.4.
DMSO diluted in medium at the same dilution was used
as control. Subsequently, medium was collected, diluted
in medium of pH 7.4 at a concentration of 1:10 (for a
final rapamycin concentration of 100 nM) and trans-
ferred on HT29 cells. The ability of rapamycin to block
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Fig. 1 Acidic extracellular pH reduces the antiproliferative efficacy of rapamycin. a HT29 cells were cultured in medium buffered to pH 7.4, 6.8 or 6.4 and
treated with rapamycin (100 nM), MK-2206 (1 μM), U0126 (10 μM) or DMSO for control. MTS proliferation assay was performed after 48 h of treatment. Bar
charts represent mean, error bars represent SD. * p< 0.05, Student’s t test compared to control cells at the same pH. b 786–0, Caki-1, Huh7, PLC-PRF/5 and
MC-38 cells were cultured at pH 7.4 or 6.4 and treated with rapamycin (100 nM) or DMSO for control. MTS proliferation assay was performed after 48 h of
treatment. Bar charts represent mean, error bars represent SD. * p< 0.05, Student’s t test compared to control cells at the same pH
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mTORC1 was assessed after 24 h by Western blot using
phosphorylation of S6 ribosomal protein as a read-out of
mTORC1 activity. We found that rapamycin previously
exposed to acidic pH still significantly decreased S6
phosphorylation (Fig. 2a). In comparison, the efficacy of
rapamycin exposed to pH 7.4 for the entire 48 h time
period was reduced, suggesting that acidity does not
inactivate rapamycin.
In order to further substantiate that mTORC1 inhib-
ition does not reduce cancer cell proliferation in acidic
conditions, we used a lentiviral short hairpin RNA
(shRNA) expressing system that downregulates the
expression of raptor and hence blocks the activity of
mTORC1. Western blot analysis confirmed the reduced
expression of raptor as well as the inhibition of
mTORC1 as evidenced by the lack of S6 ribosomal pro-
tein phosphorylation (Fig. 2b). Similarly to what we ob-
served with rapamycin, downregulation of raptor
reduced cancer cell proliferation by 43.8% (p < 0.0001) at
physiological pH but did not result in a significant anti-
proliferative effect when medium was buffered to pH 6.8
or 6.4 (Fig. 2c). Taken together, these results suggest that
blocking mTORC1 in acidic conditions does not reduce
cancer cell proliferation.
mTORC1 is inhibited by acidity
We next determined the influence of acidic pH on
mTORC1 activity. HT29 cells were exposed to medium
buffered at pH ranging from 7.4 to 6.4 and mTORC1
activity was analyzed by Western blot. We observed a
reduction of mTORC1 activity in acidic conditions as
evidenced by a decreased phosphorylation of S6 riboso-
mal protein (Fig. 3a). This reduction was already present
at pH 6.8 and maximal at pH 6.4. In contrast, AKT or
MAPK phosphorylation was not affected by acidic pH
(Fig. 3a). The reduction of mTORC1 activity by acidic
pH started already after 60 min exposure to acidity and
was completely reversible (Fig. 3b-c).
Recent studies have demonstrated that some functions
of mTORC1 are not inhibited by rapamycin [24]. For in-
stance, rapamycin only blocks the phosphorylation of
Ser65 but not Thr37/47 of 4E-BP1, although all these
residues are phosphorylated by mTORC1. We therefore
tested whether acidic pH inhibits mTORC1 completely
or only the rapamycin sensitive functions of mTORC1.
We observed that, similarly to rapamycin, acidic pH
reduced pSer65 4E-BP1 but not pThr37/47 4E-BP1 as
shown by Western blot (Fig. 3d). In contrast, the inhib-
ition of mTORC1 using interfering shRNA to raptor
blocked both Ser65 and Thr37/47 phosphorylation.
Taken together, these results illustrate that acidic pH
specifically inhibits the rapamycin sensitive functions
of mTORC1.
Sodium bicarbonate potentiates the anti-tumor efficacy
of rapamycin in vivo
According to our in vitro observations, acidity impedes
the anti-proliferative efficacy of rapamycin. Since the
tumor microenvironment is typically acid compared to
normal tissue, we next hypothesized that strategies aim-
ing to increase the intratumoral pH might potentiate the
anti-cancer efficacy of rapamycin. Recent studies have
shown that the intratumoral pH of tumors grown in
mice can be safely increased by treating mice with so-
dium bicarbonate [8]. Hence, to test our hypothesis,
nude mice bearing HT29 tumor xenografts were ran-
domized into control, rapamycin, sodium bicarbonate or
rapamycin plus sodium bicarbonate groups. We saw that
both rapamycin (growth inhibition by 71.9%) and
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Fig. 2 Acidity does not inactivate rapamycin. a HT29 cells were treated
with rapamycin (100 nM) that was previously incubated in DMEM full
medium buffered at pH 7.4 or 6.4 for 24 h. As a control HT29 cells
were also treated with fresh rapamycin. After 3 h of treatment, cells
were lysed and lysates analyzed by Western blot. b HT29 cells were
infected with lentiviruses expressing a control or raptor shRNA.
Following selection, cancer cells were lysed and Western blot analysis
was performed with the indicated antibodies. c HT29 cells generated
in panel b were exposed to various pH and proliferation assay was
carried out after 48 h of exposition. Bar charts represent mean, error
bars represent SD. * p < 0.0001, ns = not significant, Student’s t test
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sodium bicarbonate (growth inhibition by 54.4%) slowed
the growth of HT29 tumor xenografts. Combininig rapa-
mycin with sodium bicarbonate provided a stronger
anti-cancer efficacy (growth inhibition by 98.3%) than ei-
ther therapy alone (Fig. 4a). The effect was long lasting,
as after 70 days of treatment, the volume of the tumor
xenografts did still not exceed 150 mm3 (Fig. 4b). The
superior anti-cancer efficacy of a combination of rapa-
mycin and sodium bicarbonate could further be demon-
strated in C57BL/6 mice bearing MC-38 tumor
allografts (Fig. 4c). In both models, HT29 xenografts and
MC-38 allografts, histological analysis showed that
sodium bicarbonate enhances mTORC1 activity in
tumor cells as evidenced by increased phospho S6 im-
munostaining (57.8% increase in HT29 and 52.9% in
MC-38) (Figs. 5 and 6). Sodium bicarbonate also mark-
edly increased tumor necrosis (6-fold increase in HT29
and 7.7-fold increase in MC-38), and the necrotic tumor
surface was even more pronounced after a combined
treatment of sodium bicarbonate and rapamycin (9.6-
fold increase in HT29 and 10.3-fold increase in MC-38)
(Figs. 5 and 6). Finally, combining sodium bicarbonate
with rapamycin resulted in increased cancer cell apop-
tosis and reduced cancer cell proliferation as compared
to either treatment alone (Figs. 5 and 6).
Discussion
Even though targeting signaling pathways that are
deregulated in cancer has shown efficacy in cancer ther-
apy, presently, most therapies fail to cure patients. In
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Fig. 3 Reversible inhibition of mTORC1 by acidic pH. a HT29 cells were cultured for 3 h in medium buffered at the indicated pH values. Cells
were subsequently lysed and Western blot analysis was performed with the indicated antibodies. b HT29 cells were exposed to medium buffered
at pH 6.4 for the indicated time periods. Cell lysates were prepared and analyzed by Western blot for phospho S6 ribosomal protein and actin
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fact, several impediments lessen the efficacy of these
strategies, including genetic heterogeneity and resistance
mechanisms [25]. In addition, the physical and chemical
properties of the tumor microenvironment were shown
to profoundly influence tumor biology and response to
treatment. In this context, several studies support the
anti-cancer strategy of targeting the acidic pH of a
tumor [6, 26–28]. In the present study, we further
substantiate that alkalinization of tumor pH enhances
the anti-tumor efficacy of rapamycin and thus represents
a valuable adjunct to mTORC1 inhibitors. Indeed, in
accordance with others, we show that acidic pH downre-
gulates mTORC1 activity [14]. We further demonstrate
that, in acidic conditions, blocking mTORC1 with rapa-
mycin or by genetic manipulation does not prevent
cancer cell proliferation. This suggests that mTORC1
c
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Fig. 4 Sodium bicarbonate potentiates the anticancer efficacy of rapamycin. a HT29 xenograft growth curves treated with vehicle, sodium bicarbonate (200
mmol/L drinking water), rapamycin (3 mg/kg i.p. per day) or a combination of both. b HT29 xenograft growth curve treated with sodium bicarbonate (200
mmol/L drinking water) and rapamycin (3 mg/kg i.p. per day). c MC-38 allograft growth curves treated as under a. Arrows denote the start of treatment with
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participates in cancer cell proliferation only at physio-
logical pH and tumor cells proliferate independently of
mTORC1 in an acidic tumor microenvironment. Indeed,
sodium bicarbonate treatment restores mTORC1 activity
in cancer cells and a subsequent inhibition of mTORC1
allows to further reduce cancer cell proliferation (Fig. 5).
Of note, we cannot exclude that sodium bicarbonate also
affect rapamycin metabolism, leading to a better uptake
by cancer cells, resulting in a stronger inhibition of
mTORC1.
One obvious explanation for the lack of efficacy of
rapamycin in acidic conditions is its inactivation by
acidity. However, we found that the biological activity of
rapamycin is still present following incubation of rapamycin
vehicle rapamycin bicarbonate
rapamycin
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Fig. 5 Bicarbonate induces mTORC1 activity, increases necrosis and apoptosis and potentiates rapamycin efficacy. Serial sections of HT29 tumor
xenografts and MC-38 tumor allografts were stained with H & E and with phospho S6, cleaved caspase 3 and PCNA antibodies. Representative images
of immunohistochemistry are shown. Scale bar, 100 μm
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in acidic conditions (Fig. 2a). The inhibition of mTORC1
was even more pronounced when rapamycin was pre-
exposed to acidity compared to a physiological pH (Fig. 2a).
Consistent with our observation, it was reported that
rapamycin is more stable in acidic conditions [29].
Besides acidity, tumor hypoxia has also been shown to
negatively regulate mTORC1 activity [13]. Accordingly,
mTORC1 activity is mainly restricted to the non-
hypoxic tumor compartment, and the hypoxic tumor
response mediated by HIF-1 induces resistance to
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mean, error bars represent SD. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, ns = not significant, One-way ANOVA
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mTORC1 inhibitors [30]. As hypoxia promotes tumor
acidosis, a complex relationship exists between mTORC1
activity, hypoxia and acidity in tumors [2]. In addition,
acidosis affects the hypoxic tumor response by increasing
HIF-1 stability [2]. Therefore, targeting tumor acidosis
might also reduce HIF-1-mediated cancer cell responses
and by this mechanism enhance the anti-cancer efficacy of
mTORC1 inhibitors. Clearly, additional studies are needed
to further characterize the molecular relationship between
mTORC1, hypoxia and acidity in cancer.
A simple approach to increase tumor pH has been
proposed through the use of systemic buffers such as so-
dium bicarbonate [7]. Interestingly, this approach has
demonstrated remarkable anti-cancer efficacy in mouse
models. Sodium bicarbonate is sufficient to reduce
tumor growth, local invasion and metastasis in preclin-
ical models [3, 8]. Furthermore, it also prevents the de
novo-formation of prostate cancer in a mouse model of
spontaneous tumor formation [31]. Our findings further
suggest that sodium bicarbonate might be effective as an
adjunct to mTORC1 targeting therapies in order to po-
tentiate their efficacy. Whereas the use of sodium bicar-
bonate in humans over a long period of time may
induce serious side effects, a more restricted application
such as an adjuvant setting might be better tolerated.
Nevertheless, it is worth noting that long term therapy
with sodium bicarbonate has been reported in patients
with renal tubular acidosis and sickle cell anemia with-
out major side effects [32, 33]. Its feasibility in the con-
text of cancer needs, however, to be investigated. Of
note, besides sodium bicarbonate, other methods that
alter tumor pH, including proton pump inhibitors, were
shown to exert anti-cancer activity and thus represent a
therapeutic alternative, possibly better tolerated than
sodium bicarbonate [34, 35].
The mechanisms underlying the anti-tumor effects of
sodium bicarbonate need to be fully identified [36]. Here
we observe that sodium bicarbonate significantly in-
creases tumor necrosis, evoking a powerful inflamma-
tory response (Fig. 5). This suggests that pH buffering by
sodium bicarbonate influences the behavior of non-
tumor cells present in the tumor microenvironment.
Consistent with this hypothesis, acidity was shown to in-
duce an M2-like polarization of tumor associated macro-
phages which promote tumor growth [37]. Furthermore,
acidity also induces anergy of tumor-infiltrating T
lymphocytes [38]. Hence, targeting tumor acidity
might also represent an adjunct therapy to strategies
aiming to modulate the immune response against
tumor cells. Consistent with this hypothesis, a recent
study showed that neutralizing tumor acidity with
sodium bicarbonate improved the antitumor efficacy
of anti-CTLA-4 or anti PD-1 therapies as well as of
adoptive T cell transfer [39].
A discrepancy exists between our in vitro and in vivo
results. Indeed, whereas alkaline conditions promote
cancer cell proliferation in culture, it reduces tumor
growth in nude mice. One possible explanation is that
alkaline conditions favor an anti-tumor response by the
tumor microenvironment. Consistent with this hypoth-
esis, acidity promotes a tumor promoting phenotype of
macrophages [37]. Similarly, the activity of natural killer
cells is reduced in acidic conditions [40]. Further studies
are however needed to fully characterize the conse-
quences of targeting tumor acidity on the tumor
micorenvironement.
Conclusions
The present study shows that acidity acts as a novel
resistance mechanism to mTORC1 inhibitors. In this
regard, pharmacological interventions targeting tumor
pH represent a therapeutic strategy to potentiate the
anti-tumor efficacy of mTORC1 inhibitors; a new thera-
peutic approach that warrants clinical evaluation.
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